CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug

3rd August 2021 Uncategorised 0

The £100m fine sends ‘a clear message’ to the pharma sector, said the CMA

More: CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug
Source: News